{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:18:02Z","timestamp":1777637882343,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.msard.2022.104251","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T14:07:43Z","timestamp":1666015663000},"page":"104251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9118-077X","authenticated-orcid":false,"given":"M.","family":"Gaughan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8457-1748","authenticated-orcid":false,"given":"I.","family":"McGurgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Tubridy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"McGuigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.msard.2022.104251_bib0001","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.3390\/ijms21176236","article-title":"The role of the jc virus in central nervous system tumorigenesis","volume":"21","author":"Ahye","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2022.104251_bib0002","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/j.jns.2015.08.1043","article-title":"Rate of sero-conversion of anti-JC virus antibody among multiple sclerosis patients in Kuwait","volume":"357","author":"Alroughani","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2022.104251_bib0003","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/PAT.0b013e3283463558","article-title":"Immunosuppression increases latent infection of brain by JC polyomavirus","volume":"43","author":"Bayliss","year":"2011","journal-title":"Pathology"},{"issue":"2","key":"10.1016\/j.msard.2022.104251_bib0004","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ene.12304","article-title":"Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial","volume":"21","author":"Bozic","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.104251_bib0005","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2022.104251_bib0006","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/infdis\/147.4.676","article-title":"Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues","volume":"147","author":"Chesters","year":"1983","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.msard.2022.104251_bib0007","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jocn.2017.08.006","article-title":"Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population","volume":"45","author":"Correia","year":"2017","journal-title":"J. Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.msard.2022.104251_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217303","article-title":"Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia","volume":"14","author":"Evdoshenko","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2022.104251_bib0009","article-title":"Risk attitudes and risk perceptions in individuals with multiple sclerosis","volume":"2","author":"Glanz","year":"2016","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2022.104251_bib0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jns.2017.03.001","article-title":"Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients","volume":"376","author":"Heesen","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2022.104251_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174005","article-title":"Stability and predictive value of anti-JCV antibody index in multiple sclerosis: a 6-year longitudinal study","volume":"12","author":"Hegen","year":"2017","journal-title":"PLoS One"},{"issue":"Pt 11","key":"10.1016\/j.msard.2022.104251_bib0012","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1093\/brain\/awv260","article-title":"Fingolimod versus interferon beta\/glatiramer acetate after natalizumab suspension in multiple sclerosis","volume":"138","author":"Iaffaldano","year":"2015","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2022.104251_bib0013","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1212\/NXI.0000000000000199","article-title":"Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug","volume":"3","author":"Javed","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2022.104251_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000363","article-title":"Seroepidemiology of human polyomaviruses","volume":"5","author":"Kean","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.msard.2022.104251_bib0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.msard.2019.02.019","article-title":"The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings","volume":"30","author":"Kolcava","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2022.104251_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174858","article-title":"Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?","volume":"12","author":"Kr\u00e4mer","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2022.104251_bib0017","unstructured":"L. Mason, N.C., Z. Ren, I. Chang, P.-R. Ho, 2019. Low risk of Natalizumab-associated progressive multifocal leukoencephalopathy in patients who were anti-JC virus antibody negative at baseline."},{"issue":"4","key":"10.1016\/j.msard.2022.104251_bib0018","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2022.104251_bib0019","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00415-016-8372-0","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks","volume":"264","author":"Maloney","year":"2017","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.104251_bib0020","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2022.104251_bib0021","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study","volume":"83","author":"O'Connor","year":"2014","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2022.104251_bib0022","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1191\/1352458505ms1205oa","article-title":"Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis","volume":"11","author":"O\u2019Connor","year":"2005","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.msard.2022.104251_bib0023","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2022.104251_bib0024","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1352458513505353","article-title":"JC-virus seroconversion in multiple sclerosis patients receiving natalizumab","volume":"20","author":"Outteryck","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104251_bib0025","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2018001","article-title":"Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica","volume":"40","author":"Paz","year":"2018","journal-title":"Epidemiol. Health"},{"issue":"4","key":"10.1016\/j.msard.2022.104251_bib0026","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ana.21443","article-title":"Detection of JC virus DNA fragments but not proteins in normal brain tissue","volume":"64","author":"Perez-Liz","year":"2008","journal-title":"Ann. neurol."},{"issue":"12","key":"10.1016\/j.msard.2022.104251_bib0027","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00415-017-8643-4","article-title":"Natalizumab therapy is associated with changes in serum JC virus antibody indices over time","volume":"264","author":"Peters","year":"2017","journal-title":"J. neurol."},{"issue":"6","key":"10.1016\/j.msard.2022.104251_bib0028","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti\u2013JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. neurol."},{"issue":"S201","key":"10.1016\/j.msard.2022.104251_bib0029","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ane.12840","article-title":"The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy","volume":"136","author":"Reuwer","year":"2017","journal-title":"Acta Neurol. Scand."},{"issue":"15","key":"10.1016\/j.msard.2022.104251_bib0030","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2022.104251_bib0031","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/1352458517728814","volume":"24","author":"Schwab","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104251_bib0032","first-page":"563","author":"Schwab","year":"2018"},{"issue":"1","key":"10.1016\/j.msard.2022.104251_bib0033","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"Schwab","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2022.104251_bib0034","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40263-020-00716-6","article-title":"Changes in anti-jcv antibody status in a large population of multiple sclerosis patients treated with natalizumab","volume":"34","author":"Sgarlata","year":"2020","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.msard.2022.104251_bib0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"S\u00f8rensen","year":"2012","journal-title":"Mult. scler."},{"issue":"4","key":"10.1016\/j.msard.2022.104251_bib0036","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s Disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2022.104251_bib0037","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2022.104251_bib0038","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/ene.12988","article-title":"High cumulative JC virus seroconversion rate during long-term use of natalizumab","volume":"23","author":"Vennegoor","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2022.104251_bib0039","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1177\/1352458514567728","article-title":"Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Vennegoor","year":"2015","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2022.104251_bib0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamaneurol.2019.2670","article-title":"Progressive multifocal leukoencephalopathy incidence and risk stratification among natalizumab users in France","volume":"77","author":"Vukusic","year":"2020","journal-title":"JAMA Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822007556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822007556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:11:27Z","timestamp":1761901887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822007556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":40,"alternative-id":["S2211034822007556"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104251","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104251"}}